Clinical Testing News and Research

RSS

Study: Genetics could explain why environmental exposures can trigger onset of rheumatoid arthritis

A new international study has revealed how genetics could explain why different environmental exposures can trigger the onset of different forms of rheumatoid arthritis.

From The University of Manchester 27 Mar 2014

Scientists develop new method to deliver cancer-fighting drugs directly to milk ducts

One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women.

25 Mar 2014

Researchers developing new medication to tackle river blindness and elephantiasis

Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.

24 Mar 2014

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.

20 Mar 2014

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris.

19 Mar 2014

Findings reveal potential drug targets for small cell lung cancer

Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.

17 Mar 2014

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. The finding was published in this week's online edition of Oncotarget.

8 Mar 2014

New study uses Lumosity games to detect subtle cognitive impairments in patients with cirrhosis

A new study from the University of Washington has found that performance on Lumosity games can distinguish between patients with cirrhosis of the liver, pre-cirrhotic patients, and healthy controls. The study used Lumosity games as psychometric tests to detect subtle cognitive impairments in patients with cirrhosis. The study is published in the March issue of the American Journal of Gastroenterology.

6 Mar 2014

Novel HIV prevention products for women demonstrate safety in clinical studies

Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections.

5 Mar 2014

New optical device may help docs to diagnose blood coagulation status in near real time

Defective blood coagulation is one of the leading causes of preventable death in patients who have suffered trauma or undergone surgery. The body's natural defense against severe blood loss is the clotting process, in which platelets, plasma proteins, and other blood components interact to form a sticky, mesh-like structure.

26 Feb 2014

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Many vaccines, including those for influenza, polio, and measles, consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky.

18 Feb 2014

FDA accepts Regado Biosciences' IND application for REG2

Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.

13 Feb 2014

GenVec achieves third milestone for development of treatments for hearing and balance disorderstion

GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders.

13 Feb 2014

Two oncogenes work together to sustain population of cells in lung squamous cell carcinoma

Patients with a common form of lung cancer — lung squamous cell carcinoma — have very few treatment options. That situation may soon change.

10 Feb 2014

Novel combined therapy for treatment of septic patients in ICU

Septic shock is caused by excessive and systemic reaction of the entire body against infectious agents, in most cases of bacterial origin. The number of deaths by septic shock in intensive care units is very high and is still increasing, despite numerous large scale clinical trials.

9 Feb 2014

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.

5 Feb 2014

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.

29 Jan 2014

UCSF awarded grant of $2.7M for collaborative project aimed at reducing premature births

UC San Francisco has been awarded a Bill & Melinda Gates Foundation grant of $2.7 million over three years for a collaborative project aimed at reducing premature births.

29 Jan 2014

CUMC researchers identify gene that appears to play major role in motor neuron degeneration in ALS

Columbia University Medical Center researchers have identified a gene, called matrix metalloproteinase-9 (MMP-9), that appears to play a major role in motor neuron degeneration in amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. The findings, made in mice, explain why most but not all motor neurons are affected by the disease and identify a potential therapeutic target for this still-incurable neurodegenerative disease. The study was published today in the online edition of the journal Neuron.

23 Jan 2014

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma.

23 Jan 2014

Clinical Testing News and Research

Study: Genetics could explain why environmental exposures can trigger onset of rheumatoid arthritis

Scientists develop new method to deliver cancer-fighting drugs directly to milk ducts

Researchers developing new medication to tackle river blindness and elephantiasis

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Findings reveal potential drug targets for small cell lung cancer

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

New study uses Lumosity games to detect subtle cognitive impairments in patients with cirrhosis

Novel HIV prevention products for women demonstrate safety in clinical studies

New optical device may help docs to diagnose blood coagulation status in near real time

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

FDA accepts Regado Biosciences' IND application for REG2

GenVec achieves third milestone for development of treatments for hearing and balance disorderstion

Two oncogenes work together to sustain population of cells in lung squamous cell carcinoma

Novel combined therapy for treatment of septic patients in ICU

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

UCSF awarded grant of $2.7M for collaborative project aimed at reducing premature births

CUMC researchers identify gene that appears to play major role in motor neuron degeneration in ALS

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

Industry Focus eBook - Clinical & Point of Care Diagnostics (1st edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News